Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zimmer Biomet’s filings rarely read like light literature—hundreds of pages detail knee, hip, and S.E.T. sales, FDA clearances, and the cost of bringing robotic surgery to market. Sorting through that volume to spot revenue shifts or a device-recall risk is a real challenge.
Stock Titan solves that problem. Our AI turns dense disclosures into plain language so you can understand Zimmer Biomet SEC documents with AI in minutes, not hours. Need to track Zimmer Biomet insider trading Form 4 transactions? We stream Form 4 insider transactions in real-time and flag unusual executive stock moves. Trying to compare margins across segments? The quarterly earnings report 10-Q filing is summarised automatically, while key trends are highlighted for fast Zimmer Biomet earnings report filing analysis.
You’ll find every form the moment it hits EDGAR—10-K annual report simplified, 8-K material events explained, proxy statement executive compensation breakdowns, and each Zimmer Biomet 8-K material events explained for device launches or recalls. Our platform layers AI-powered summaries, searchable text, and red-line comparisons so you can:
- Monitor Zimmer Biomet executive stock transactions Form 4 before material events
- Follow segment-level revenue trends across knees, hips, and robotics
- Review risk-factor changes without rereading 300 pages
Whether you’re an analyst asking “Where can I find Zimmer Biomet’s quarterly earnings report 10-Q filing?” or a surgeon-investor wondering “How to read Zimmer Biomet’s 10-K annual report”, our exhaustive library keeps you current with real-time updates and expert context. Complex orthopedic disclosures, explained simply.
Zimmer Biomet Holdings (ZBH) reported an insider equity transaction by its Exec VP & CFO, Suketu Upadhyay. On November 10, 2025, 10,632 performance-based RSUs vested and were converted into common stock at $0 per share. To cover taxes, 4,731 shares were withheld at a price of $87.73 per share.
Following these transactions, the executive’s directly held common stock totaled 54,754 shares. The filing notes these RSUs each represented the right to receive one share of common stock, and the earned performance-based RSUs vested on November 10, 2025.
Zimmer Biomet (ZBH) reported third‑quarter results. Net sales were $2,001.4 million, up from $1,824.2 million. Operating profit rose to $351.3 million from $279.5 million, while net earnings attributable to the company were $230.9 million versus $249.1 million a year ago. Diluted EPS was $1.16 (prior year $1.23). By category, Q3 sales were Knees $792.4 million, Hips $506.2 million, S.E.T. $541.5 million, and Technology & Data, Bone Cement and Surgical $161.3 million.
For the first nine months, net sales reached $5,987.7 million with operating cash flow of $1,179.7 million. The balance sheet showed cash and cash equivalents of $1,292.7 million and long‑term debt of $7,512.6 million as of September 30, 2025. The company completed the Paragon 28 acquisition, paying $1,241.5 million in cash plus contingent consideration fair‑valued at $35.0 million, recording $635.6 million of goodwill. During 2025, Zimmer Biomet issued new senior notes (including $1,748.1 million in U.S. dollar notes and $744.0 million in Swiss Notes) and redeemed $863.0 million of 2025 notes. A quarterly dividend of $0.24 per share was declared.
Zimmer Biomet Holdings, Inc. furnished an 8-K announcing a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and its information is incorporated by reference in the report.
The Item 2.02 information, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated into other filings except by specific reference. An additional Exhibit 104 (Cover Page Interactive Data File) is included.
Zimmer Biomet Holdings (ZBH) reported an insider equity award on a Form 4. The company’s Executive Vice President and CFO received 10,632 restricted stock units (RSUs), recorded as an acquisition at $0 per unit and held directly.
The RSUs were part of a performance-based grant made on September 1, 2023, with results measured over October 1, 2024 to September 30, 2025. On October 24, 2025, the final outcome was determined, and 10,632 RSUs were earned. Each RSU represents the right to receive one share of Zimmer Biomet common stock. The earned RSUs are scheduled to vest on November 10, 2025.
Devdatt Kurdikar, a Director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 140.163 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The derivative units convert on a 1-for-1 basis into common stock and are scheduled to be settled in shares within sixty days after the director’s service ends. The report shows 1,613.887 shares of common stock beneficially owned following the reported transaction, and it notes 3.428 phantom units were added on 07/31/2025 via the plan’s dividend reinvestment provision.
Kolli Sreelakshmi, a director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 159.276 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The units convert 1-for-1 into common shares and are to be settled in company stock within sixty days after the director stops service. Following the transaction, the report shows beneficial ownership of 5,393.594 shares (including 13.119 units added via dividend reinvestment on 07/31/2025). The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Maria Teresa Hilado, a director of Zimmer Biomet Holdings, Inc. (ZBH), reported an acquisition of 344.036 phantom stock units on 09/30/2025 under the companys Deferred Compensation Plan for Non-Employee Directors. The phantom units convert 1-for-1 into common stock value and are to be settled in cash in ten annual installments commencing within 60 days after the end of the calendar year in which her director service ends. The report notes 26.33 of the units were credited on 07/31/2025 via the plans dividend reinvestment provision. Following the transaction the filing shows total beneficial ownership of 10,875.718 shares.
Robert Hagemann, a non-employee director of Zimmer Biomet Holdings, Inc. (ZBH), was granted 280.326 phantom stock units on 09/30/2025 under the company's Deferred Compensation Plan for Non-Employee Directors. The units convert on a 1-for-1 basis into common stock value and are recorded at a per-unit price of $98.1, producing a reported aggregate value of $31,207.57. The filing notes that 79.18 of the units were accrued on 07/31/2025 under a dividend reinvestment provision. The phantom units are payable in cash in five annual installments beginning within 60 days after the calendar year in which the director's service ends.
Insider transaction disclosed for ZIMMER BIOMET HOLDINGS, INC. (ZBH). The reporting person, Sang Yi, Group President, Asia Pacific and an officer and director, reported a sale of 1,200 shares of common stock on 09/11/2025 at a price of $103.585 per share. After the sale, the filing shows 18,584 shares beneficially owned by the reporting person. The filing also notes that the reported beneficial ownership includes 160 shares acquired under the Employee Stock Purchase Plan on June 30, 2025. The Form 4 was signed by an attorney-in-fact on 09/15/2025.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
